BioSpace News Archive

BioArctic AB will be strengthening its management team in 2020 through two strategic recruitments.

Owlstone Medical will receive funding to deploy Breath Biopsy® as part of EPHOR

Dr. Spychala Brings Patient-Centricity and Rare Disease Clinical Research Expertise to New Role

Aligos Chief Executive Officer Lawrence Blatt told BioSpace that the different assets in development address different components of the infection.

The National Eye Hospital of the Quinze- Vingts in Paris and GenSight Biologics announced that the French Competent Authority, the National Drug Safety Agency, granted a named patient Temporary Authorization for Use for LUMEVOQTM to the CHNO of the Quinze-Vingts.

Amgen announced the 240,000-square-foot facility, which is still under construction, will house the company’s Bay Area employees focused on cardiometabolic, inflammation and oncology, research.

At the six-year mark, 90.6% of patients in the Perjeta cohort have not had breast cancer return, compared to 87.8% in the placebo arm. This comes to an absolute benefit of 2.8%.

Research shows modulation of the Hedgehog and androgen signaling pathways to discontinue the vicious circle leading to inflammation in the central nervous system and chronic demyelination

Creoptix AG announced the appointment of Line Stigen Raquet as Chief Executive Officer with effect from beginning of January 2020.

Locana, Inc., a leading RNA-targeting gene therapy company, announced the appointment of James Burns, Ph.D., as chief executive officer, as a key step in expanding the experienced leadership team and as part of a planned transition of the company’s director and recent CEO, Jeffrey M. Ostrove, Ph.D., to continue service as director..